Excited to share preliminary data from the Century Therapeutics, Inc ELiPSE-1 trial and a case study of a patient who maintained a CR while receiving four 28 day cycles of CNTY-101 at the lowest dose level. CNTY-101 is engineered with six precision edits, including ALLO-EVASION technology to enable repeat dosing. Importantly, this patient's first two cycles included lymphodepletion while the next two did not. No pre-existing or induced anti-drug antibodies were detected and each infusion demonstrated comparable kinetics. These early results are encouraging for both oncology and non-oncology indications, where the side effect profile of lymphodepletion may be prohibitive. #ipsc #celltherapy #geneediting #oncology #autoimmune
We look forward to presenting initial data from our ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell #lymphomas at the 65th American Society of Hematology Annual Meeting and Exposition on December 9, 2023 in San Diego. Read the press release: https://bit.ly/3Mr8f6u
Very exciting! Looking forward to it, Adrienne.
Biotech Executive
10moInteresting Carlo- I look forward to following this study